What diseases are the indications for ivonib/Tosovo included?

Ivosidenib/Tosovo (Ivosidenib) is an innovative oral targeted drug mainly used to treat malignant diseases related to IDH1 gene mutations. IDH1 (isocitrate dehydrogenase 1) mutations are prominent in certain types of tumor cells. Such mutations can lead to abnormal accumulation of 2-hydroxyglutarate, thereby affecting cell metabolism and differentiation, and promoting tumor growth. Ivonib, as a selective IDH1 inhibitor, can block this metabolic abnormality and restore the normal differentiation process of tumor cells, thereby inhibiting tumor progression.

Clinically, ivosidenib is primarily approved for the treatment of adult patients with acute myeloid leukemia (AML) who have IDH1 mutations and often have high-risk features or who have relapsed after prior treatment. By targeting IDH1 mutations, ivosidenib provides a precision treatment option and brings new hope to patients for whom traditional chemotherapy has limited efficacy. In addition, ivonib is also used in some patients with unresectable cholangiocarcinoma (CCA) and myelodysplastic syndrome (MDS), especially those with IDH1 mutation-positive late-stage cases. With the development of precision medicine, this type of targeted therapy is gradually becoming the standard treatment plan for IDH1-related tumors.

The selection of indications for ivonib reflects the trend of precision in modern cancer treatment. Through genetic mutation testing, doctors can identify which patients are most likely to benefit from the drug and avoid unnecessary drug exposure and potential side effects. This medication strategy not only improves the therapeutic effect, but also provides individualized treatment plans for tumor patients. The guidelines recommend that IDH1 gene testing be performed before using ivonib to ensure that the patient meets the indication requirements.

In general, the indications of ivonib/Tosovo are mainly focused on patients with acute myeloid leukemia and advanced cholangiocarcinoma who are positive for IDH1 gene mutations. It provides precise and innovative treatment options for this type of high-risk patients, and reflects the application trend of combining targeted drugs with genetic testing in modern oncology.

Reference: https://www.tibsovo.com/